AIM2 and cancer: The deletion of AIM2 and/or NLRP3 mitigated the bone loss caused by doxorubicin, shedding lights on the potential association of AIM2 inflammasome inhibitors with adjuvant therapy to limit the risk of osteoporosis and fractures in cancer patients treated with chemotherapy.